aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

Stock Information for Axsome Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Axsome Therapeutics Inc.

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT(TM) Study in Pulmonary Sarcoidosis
aTyr Pharma to Present at Upcoming Investor Conferences
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT(TM) Clinical Trial Participants
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.